1. Indonesia Stocks

  2. •

    Health services

  3. •

    Hospital/Nursing management
PT Siloam International Hospitals Tbk Reg-S

PT Siloam International Hospitals Tbk Reg-S

IIDX:SILO
1,860.00
IDR
+10.00
(+0.54%)
92.16EPS
25.12P/E
28.70TMarket Cap
Oct 23Next Earn
PT Siloam International Hospitals Tbk Reg-S
IDX:SILO
(Indonesia Stock Exchange)

Recent

price

1,860.00

P/E

ratio

25.12

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
IDR
267.5
153.97
218.62
292.34
353.3
439.97
545.34
484.06
458.6
539.59
547.21
725.37
966.73
861.68
940.32
989.3
1,020.45
Revenue per Share
17.52
5.35
6.17
5.82
7.6
7.47
9.06
8.54
1.24
-26.05
8.94
52.12
70.74
93.27
69.49
85.68
87.99
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.64
- -
- -
- -
- -
- -
17.36
25.38
19.66
20
- -
- -
Dividend per Share
16.99
22.34
28.51
170.41
175.02
184.44
298.2
483.82
483.35
456.81
461.3
498.08
536.7
609.51
659.8
746.55
791.59
Book Value per Share
15.89
8.81
21.03
150.52
143.51
152.82
266.36
447.96
445.19
420.29
422.18
457.92
496.86
572.05
617.3
702.17
746.24
Tangible Book Value per Share
3,852
8,179
8,179
8,564
9,456
9,419
9,477
10,961
13,006
13,006
12,993
12,934
9,846
12,987
12,982
12,986
12,988
Basic Weighted Avg Shares
1,030,472
1,259,349
1,788,083
2,503,600
3,340,793
4,144,118
5,168,363
5,305,996
5,964,650
7,017,919
7,110,124
9,381,891
9,518,012
11,190,511
12,207,563
12,847,434
13,253,277
Sales/Revenue/Turnover
9.77
7.03
5.12
3.14
5.4
5.1
5.64
5.6
4.17
3.53
6.16
12.1
11.7
15.95
14.99
13.63
13.28
Operating Margin (%)
5,579
22,078
31,921
52,481
80,774
101,659
104,655
137,452
240,331
273,106
484,424
748,296
798,506
810,317
861,813
1,028,327
1,067,649
Depreciation Expense
67,477
43,740
50,461
49,870
71,843
70,396
85,901
93,566
16,182
-338,772
116,163
674,117
696,495
1,211,283
902,152
1,112,663
1,142,844
Net Income, GAAP
23.19
34.4
32.54
30.06
34.84
41.65
42.71
48.25
84.12
- -
59.68
28.03
27.83
25.17
30.16
24.65
24.67
Effective Tax Rate (%)
6.55
3.47
2.82
1.99
2.15
1.7
1.66
1.76
0.27
-4.83
1.63
7.19
7.32
10.82
7.39
8.66
8.62
Profit Margin (%)
-5,457
150,883
189,104
611,544
358,453
326,305
1,180,814
1,298,595
786,514
474,840
740,217
1,306,108
508,866
498,202
-768,250
-909,117
-1,386,925
Working Capital
247,427
509,538
853,540
430,035
446,339
377,788
115,125
147,116
124,327
104,469
501,855
303,246
221,864
151,974
95,684
54,921
39,938
LT Debt
137,579
178,963
244,641
1,638,992
1,659,831
1,739,952
3,129,070
6,313,514
6,316,675
5,987,681
6,018,371
6,523,942
7,051,519
8,047,636
8,751,628
9,928,969
10,543,143
Total Equity
- -
8.13
6.7
3.42
4.5
4.32
4.71
2.32
0.47
- -
2.44
10.64
10.01
15.91
9.89
11.04
10.89
Return on Invested Capital (%)
- -
11.09
6.03
3.4
4.71
4.83
3.37
1.94
0.14
- -
2.11
9.85
9.69
14.94
8.87
10.02
9.79
Return on Capital (%)
- -
27.19
24.27
5.41
4.4
4.14
3.53
1.99
0.26
-5.54
1.95
10.87
10.4
16.29
10.94
12.18
11.96
Return on Common Equity (%)

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,581,785
2,091,909
2,410,417
LT Borrowings
- -
- -
- -
LT Finance Leases
54,921
40,816
39,938
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12,988
12,988
12,988
Market Capitalization
35,585,760
35,196,135
28,703,387

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,339,212
3,415,717
3,596,776
Cash, Cash Equivalents & STI
1,178,203
1,216,232
1,238,032
Accounts Receivable, Net
1,674,841
1,698,852
1,880,233
Inventories
234,107
204,711
208,570
Total Current Liabilities
4,248,329
4,792,423
4,983,701
Payables & Accruals
- -
- -
- -
ST Debt
1,581,785
2,091,909
2,410,417
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.98%
10.56%
13.45%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-182.42%
111.07%
23.33%
Sales/Revenue/Turnover
12.41%
13.06%
5.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,027,020
2,989,562
3,106,591
3,084,390
12,207,563
2025
3,036,971
3,067,977
- -
3,421,901
12,847,434
2026
3,277,776
3,485,623
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.05
23.15
24.7
20.59
69.49
2025
18.95
16.23
- -
27.05
85.68
2026
21.56
23.15
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
20
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP)
Max Healthcare Institute Ltd (NSE:MAXHEALTH)
Fortis Healthcare Ltd. (NSE:FORTIS)
Bangkok Dusit Medical Services Public Co. Ltd. (SET:BDMS)
Yatharth Hospital and Trauma Care Services Limited (NSE:YATHARTH)
HCA Healthcare, Inc. (NYSE:HCA)
Business
PT Siloam International Hospitals Tbk (SILO.JK) operates Indonesia's largest private hospital network, providing comprehensive healthcare services including specialized medical treatments, diagnostic imaging, laboratory testing, radiation therapy, emergency care, surgical procedures across multiple disciplines such as cardiology, oncology, neurology, orthopedics, obstetrics, pulmonology, and urology; general, pre-marital, heart, kidney, cancer, and visa medical check-ups; teleconsultation, home healthcare, genomic testing, and vaccination services; as well as advanced interventions like transplantation, gamma knife surgery, and brainstem surgery. The company manages over 41 hospitals and 25 clinics equipped with state-of-the-art facilities and staffed by specialists and sub-specialists, serving patients across diverse socio-economic backgrounds with a focus on accessibility and quality care. Founded in 1996 and headquartered in Tangerang, Banten, Indonesia, in the Pelita Harapan University Medical Faculty Building, Siloam extends its operations nationwide across Java, Sumatra, Bali, Kalimantan, Sulawesi, Nusa Tenggara Timur, Nusa Tenggara Barat, and Bangka Belitung, targeting individual patients, corporate clients, and government programs in the healthcare facilities and services sector. In recent developments, CVC Capital Partners acquired a controlling stake exceeding US$1 billion from PT Lippo Karawaci Tbk in 2024, establishing a joint venture structure while Lippo retains a minority interest, followed by Sight Investment Company Pte. Limited increasing its ownership to 63% through the purchase of 1.04 billion shares in December 2024. In January 2025, Marubeni Corporation signed a Memorandum of Strategic Partnership to deepen collaboration, including joint ventures in outsourcing services like laboratory testing and specialized hospitals, building on Marubeni's 2020 equity investment. The company continues expansion with new facilities such as Siloam Clinic Soe in East Nusa Tenggara in late 2023 and fertility clinic services at Siloam Hospitals Lippo Village, alongside ongoing programs like SELANGKAH breast cancer screening and uro-nephrology symposia to enhance medical expertise. Siloam, a subsidiary of Sight Investment Company Pte. Limited, maintains strategic ties with Lippo Group entities and reported nine-month earnings through September 30, 2025, underscoring its growth amid Indonesia's rising healthcare demands.